5 Best Buy-the-Dip Stocks To Buy Now

Page 1 of 5

In this article, we will take a look at the 5 best buy-the-dip stocks to buy now. If you want to see more stocks in this selection, go to the 11 Best Buy-the-Dip Stocks To Buy Now.

5. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Number of Hedge Fund Holders: 34

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a Durham, North Carolina-based commercial-stage biotechnology company that is focused on developing therapeutics through its proprietary discovery engine.

In a research note issued to investors on December 15, Ken Cacciatore at Cowen assigned BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stock an Outperform rating with a target price of $25. The analyst believes that the management showed its intent to preserve capital as it discontinued the development of BCX9930 due to a lack of commercial viability. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) pulled the plug now instead of waiting until mid-2023. This will now shift the company’s complete focus to the development of complement inhibitor BCX10013. The analyst added that despite the discontinuation, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has the potential to create value and become an attractive potential takeover target for big pharma companies.

As of Q3 2022, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was held by 34 hedge funds.

Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)

Page 1 of 5